| Revista: | Annals of hepatology |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000411830 |
| ISSN: | 1665-2681 |
| Autors: | Tamori, Akihiro1 Kioka, Kiyohide2 Sakaguchi, Hiroki3 Enomoto, Masaru1 Hai, Hoang1 Kawamura, Etsushi1 Hagihara, Atsushi1 Hideki Fujii1 Uchida-Kobayashi, Sawako1 Iwai, Shuji1 Morikawa, Hiroyasu1 Murakami, Yoshiki1 Kawasaki, Yasuko2 Tsuruta, Daisuke1 Kawada, Norifumi1 |
| Institucions: | 1Osaka City University, Graduate School of Medicine, Osaka. Japón 2Osaka City General Hospital, Department of Hepatology, Osaka. Japón 3Izumi Municipal Hospital, Internal Medicine, Izumi, Osaka. Japón |
| Any: | 2015 |
| Període: | Ene-Feb |
| Volum: | 14 |
| Número: | 1 |
| Paginació: | 28-35 |
| País: | México |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Analítico, descriptivo |
| Resumen en inglés | Anemia is the most common adverse event in patients with chronic hepatitis C virus (HCV) treated with telaprevir (TVR) combined triple therapy. We examined the effects of drug dose adjustment on anemia and a sustained viral response (SVR) during combination therapy. Material and methods. This study enrolled 62 patients treated with TVR (2,250 mg) for 12 weeks plus pegylated interferon-alpha-2b and ribavirin for 24 weeks. The patients were assigned randomly to the TVR-standard or -reduced groups before treatment. At the occurrence of anemia (hemoglobin < 12 g/dL), the TVR-reduced group received 1500 mg TVR plus the standard dose of ribavirin, whereas the TVR-standard group received the standard TVR dose (2,250 mg) and a reduced dose of ribavirin (200 mg lower than prescribed originally). The safety and SVR at 24 weeks were compared between the TVR-standard (n = 28) and TVR-reduced (n = 25) groups. Results. No differences in the proportion of patients who became HCV RNA-negative were detected between the TVRstandard and -reduced groups (72 and 72% at week 4, 79 and 84% at the end of treatment, and 76 and 80% at SVR24, respectively). Two groups had comparable numbers of adverse events, which led to the discontinuation of TVR in 14 patients of TVR-standard group and in 14 of TVR-reduced group. A lower incidence of renal impairment was observed in the TVR-reduced group (6%) than the TVR-standard group (11%, not statistically significant). Conclusions. TVR dose adjustment could prevent anemia progression without weakening the anti-viral effect during triple therapy in HCV-patients |
| Disciplines | Medicina |
| Paraules clau: | Farmacología, Gastroenterología, Hepatitis C, Hepatitis crónica, Telaprevir, Peginterferón, Ribavirina, Efectos adversos, Anemia, Respuesta viral |
| Keyword: | Medicine, Gastroenterology, Pharmacology, Hepatitis C, Chronic hepatitis, Telaprevir, Peginterferon, Ribavirin, Adverse effects, Anemia, Viral response |
| Text complet: | Texto completo (Ver PDF) |
